Pricing delay deprives Greek patients of Benlysta, Tobi, Victrelis and more
This article was originally published in Scrip
Executive Summary
A 19-month delay in the issuance of a drug price bulletin in Greece has meant that patients with numerous severe diseases have been unable to access innovative treatments despite EU approval and their availability elsewhere in Europe.